Creating an IPO Alternative for Small Biotechs
Of the four Congressional bills aimed at providing small companies with new fundraising options, H.R. 1070 – which would allow private firms to raise up to $50 million publicly and trade their shares without the expense of becoming a reporting company – is likely to have the most immediate impact on biotech.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter